Symbols / VTRS
VTRS Chart
About
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 16.38B |
| Enterprise Value | 29.56B | Income | -3.51B | Sales | 14.30B |
| Book/sh | 12.78 | Cash/sh | 1.31 | Dividend Yield | 3.38% |
| Payout | 9.60% | Employees | 30000 | IPO | — |
| P/E | — | Forward P/E | 5.35 | PEG | — |
| P/S | 1.15 | P/B | 1.11 | P/C | — |
| EV/EBITDA | 7.47 | EV/Sales | 2.07 | Quick Ratio | 0.69 |
| Current Ratio | 1.38 | Debt/Eq | 99.91 | LT Debt/Eq | — |
| EPS (ttm) | -3.00 | EPS next Y | 2.66 | EPS Growth | — |
| Revenue Growth | 5.00% | Earnings | 2026-05-07 | ROA | 1.96% |
| ROE | -21.08% | ROIC | — | Gross Margin | 39.55% |
| Oper. Margin | 7.78% | Profit Margin | -24.58% | Shs Outstand | 1.15B |
| Shs Float | 1.14B | Short Float | 2.63% | Short Ratio | 2.71 |
| Short Interest | — | 52W High | 16.47 | 52W Low | 6.85 |
| Beta | 0.80 | Avg Volume | 9.96M | Volume | 8.86M |
| Target Price | $15.50 | Recom | Buy | Prev Close | $14.04 |
| Price | $14.22 | Change | 1.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.50
Mean price target
2. Current target
$14.22
Latest analyst target
3. DCF / Fair value
$38.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.22
Low
$12.00
High
$20.00
Mean
$15.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | main | Piper Sandler | Neutral → Neutral | $12 |
| 2026-01-16 | up | Argus Research | Hold → Buy | $15 |
| 2025-12-09 | init | Barclays | — → Overweight | $15 |
| 2025-10-15 | init | Truist Securities | — → Buy | $15 |
| 2025-06-06 | init | Goldman Sachs | — → Neutral | $10 |
| 2025-03-07 | main | Jefferies | Buy → Buy | $13 |
| 2025-03-05 | reit | Piper Sandler | Neutral → Neutral | $10 |
| 2025-02-28 | main | Barclays | Underweight → Underweight | $9 |
| 2025-02-28 | main | B of A Securities | Underperform → Underperform | $10 |
| 2024-12-06 | reit | Piper Sandler | Neutral → Neutral | $14 |
| 2024-11-08 | main | Barclays | Underweight → Underweight | $12 |
| 2024-03-28 | reit | Piper Sandler | Neutral → Neutral | $13 |
| 2023-11-22 | main | Piper Sandler | Neutral → Neutral | $11 |
| 2023-10-23 | down | B of A Securities | Neutral → Underperform | $9 |
| 2023-06-23 | down | Barclays | Equal-Weight → Underweight | $11 |
| 2023-04-25 | down | Barclays | Overweight → Equal-Weight | $11 |
| 2023-04-24 | down | Barclays | Overweight → Equal-Weight | $11 |
| 2023-02-28 | main | Barclays | — → Overweight | $16 |
| 2023-02-17 | down | BMO Capital | Outperform → Market Perform | $14 |
| 2023-02-01 | main | Barclays | — → Overweight | $15 |
- Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis Fri, 06 Mar 2026 05
- Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance Mon, 09 Feb 2026 08
- Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend - PR Newswire hu, 26 Feb 2026 08
- Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq Wed, 04 Mar 2026 14
- AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys. - Barron's Fri, 27 Feb 2026 18
- Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - StockStory Mon, 02 Mar 2026 08
- $VTRS ($VTRS) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 08
- FDA to review eye drop that targets age-related blurry near vision - Stock Titan Wed, 25 Feb 2026 08
- Is Viatris (VTRS) Stock Undervalued Right Now? - Nasdaq ue, 28 Oct 2025 07
- Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
- A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance Fri, 27 Feb 2026 08
- 3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Yahoo Finance ue, 21 Oct 2025 07
- Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance Fri, 18 Jul 2025 07
- UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Yahoo Finance Sat, 28 Feb 2026 17
- Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance Fri, 23 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -119.58M | -79.63M | -45.59M | -10.65M |
| TaxRateForCalcs | 0.04 | 0.21 | 0.21 | 0.26 |
| NormalizedEBITDA | 2.52B | 3.20B | 3.73B | 6.47B |
| TotalUnusualItems | -2.92B | -379.20M | -217.10M | -40.80M |
| TotalUnusualItemsExcludingGoodwill | -2.92B | -379.20M | -217.10M | -40.80M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.51B | -634.20M | 54.70M | 2.08B |
| ReconciledDepreciation | 2.80B | 2.89B | 2.74B | 3.03B |
| ReconciledCostOfRevenue | 9.29B | 9.12B | 8.99B | 9.77B |
| EBITDA | -395.40M | 2.82B | 3.52B | 6.43B |
| EBIT | -3.19B | -73.20M | 776.00M | 3.41B |
| NetInterestIncome | -471.30M | -550.00M | -573.10M | -592.40M |
| InterestExpense | 471.30M | 550.00M | 573.10M | 592.40M |
| NormalizedIncome | -717.88M | -334.63M | 226.21M | 2.11B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.51B | -634.20M | 54.70M | 2.08B |
| TotalExpenses | 14.05B | 14.35B | 14.44B | 14.61B |
| TotalOperatingIncomeAsReported | -2.66B | 10.10M | 766.20M | 1.61B |
| DilutedAverageShares | 1.17B | 1.19B | 1.21B | 1.22B |
| BasicAverageShares | 1.17B | 1.19B | 1.20B | 1.21B |
| DilutedEPS | -3.00 | -0.53 | 0.05 | 1.71 |
| BasicEPS | -3.00 | -0.53 | 0.05 | 1.71 |
| DilutedNIAvailtoComStockholders | -3.51B | -634.20M | 54.70M | 2.08B |
| NetIncomeCommonStockholders | -3.51B | -634.20M | 54.70M | 2.08B |
| NetIncome | -3.51B | -634.20M | 54.70M | 2.08B |
| NetIncomeIncludingNoncontrollingInterests | -3.51B | -634.20M | 54.70M | 2.08B |
| NetIncomeContinuousOperations | -3.51B | -634.20M | 54.70M | 2.08B |
| TaxProvision | -150.10M | 11.00M | 148.20M | 734.60M |
| PretaxIncome | -3.67B | -623.20M | 202.90M | 2.81B |
| OtherIncomeExpense | -3.45B | -462.50M | -207.30M | 1.75B |
| OtherNonOperatingIncomeExpenses | -530.60M | -83.30M | 9.80M | 1.79B |
| SpecialIncomeCharges | -2.92B | -379.20M | -217.10M | -40.80M |
| OtherSpecialCharges | 131.20M | 324.40M | 136.70M | 40.80M |
| ImpairmentOfCapitalAssets | 2.94B | 321.00M | 580.10M | |
| RestructuringAndMergernAcquisition | -151.40M | 54.80M | 80.40M | 11.10M |
| NetNonOperatingInterestIncomeExpense | -471.30M | -550.00M | -573.10M | -592.40M |
| InterestExpenseNonOperating | 471.30M | 550.00M | 573.10M | 592.40M |
| OperatingIncome | 253.50M | 389.30M | 983.30M | 1.66B |
| OperatingExpense | 4.76B | 5.23B | 5.46B | 4.84B |
| ResearchAndDevelopment | 965.90M | 808.70M | 805.20M | 662.20M |
| SellingGeneralAndAdministration | 3.79B | 4.43B | 4.65B | 4.18B |
| GrossProfit | 5.01B | 5.62B | 6.44B | 6.50B |
| CostOfRevenue | 9.29B | 9.12B | 8.99B | 9.77B |
| TotalRevenue | 14.30B | 14.74B | 15.43B | 16.26B |
| OperatingRevenue | 23.73B | 24.91B | 25.69B | 27.66B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 94.18M | 40.48M | 21.24M | |
| OrdinarySharesNumber | 1.15B | 1.19B | 1.20B | 1.21B |
| ShareIssued | 1.25B | 1.23B | 1.22B | 1.21B |
| NetDebt | 13.09B | 13.30B | 17.13B | 18.01B |
| TotalDebt | 14.70B | 14.31B | 18.37B | 19.53B |
| TangibleBookValue | -7.15B | -7.57B | -8.58B | -11.96B |
| InvestedCapital | 29.12B | 32.67B | 38.59B | 40.34B |
| WorkingCapital | 2.69B | 3.74B | 5.20B | 3.89B |
| NetTangibleAssets | -7.15B | -7.57B | -8.58B | -11.96B |
| CapitalLeaseObligations | 287.50M | 266.40M | 248.40M | 262.00M |
| CommonStockEquity | 14.71B | 18.64B | 20.47B | 21.07B |
| TotalCapitalization | 27.19B | 32.67B | 36.66B | 39.09B |
| TotalEquityGrossMinorityInterest | 14.71B | 18.64B | 20.47B | 21.07B |
| StockholdersEquity | 14.71B | 18.64B | 20.47B | 21.07B |
| GainsLossesNotAffectingRetainedEarnings | -2.71B | -3.21B | -2.75B | -2.76B |
| OtherEquityAdjustments | -2.71B | -3.21B | -2.75B | -2.76B |
| ForeignCurrencyTranslationAdjustments | -3.39B | -1.80B | ||
| MinimumPensionLiabilities | 268.50M | 32.20M | ||
| UnrealizedGainLoss | -2.30M | 0.00 | ||
| TreasuryStock | 1.01B | 504.30M | 251.80M | 0.00 |
| RetainedEarnings | -388.30M | 3.42B | 4.64B | 5.18B |
| AdditionalPaidInCapital | 18.80B | 18.92B | 18.81B | 18.65B |
| CapitalStock | 12.50M | 12.30M | 12.20M | 12.10M |
| CommonStock | 12.50M | 12.30M | 12.20M | 12.10M |
| TotalLiabilitiesNetMinorityInterest | 22.48B | 22.87B | 27.22B | 28.95B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.39B | 17.09B | 19.44B | 22.20B |
| OtherNonCurrentLiabilities | 962.00M | 821.60M | 388.70M | 555.50M |
| EmployeeBenefits | 425.90M | 467.90M | 504.30M | 544.60M |
| NonCurrentAccruedExpenses | 116.30M | 128.50M | 59.20M | 60.40M |
| TradeandOtherPayablesNonCurrent | 332.60M | 341.90M | 399.30M | 414.60M |
| NonCurrentDeferredLiabilities | 892.00M | 1.11B | 1.74B | 2.43B |
| NonCurrentDeferredTaxesLiabilities | 892.00M | 1.11B | 1.74B | 2.43B |
| LongTermDebtAndCapitalLeaseObligation | 12.66B | 14.22B | 16.35B | 18.20B |
| LongTermCapitalLeaseObligation | 178.10M | 179.30M | 165.40M | 181.40M |
| LongTermDebt | 12.48B | 14.04B | 16.19B | 18.02B |
| CurrentLiabilities | 7.09B | 5.78B | 7.78B | 6.75B |
| OtherCurrentLiabilities | 989.90M | 1.34B | 1.41B | 1.24B |
| CurrentDebtAndCapitalLeaseObligation | 2.04B | 87.70M | 2.02B | 1.33B |
| CurrentCapitalLeaseObligation | 109.40M | 87.10M | 83.00M | 80.60M |
| CurrentDebt | 1.93B | 600.00K | 1.93B | 1.25B |
| OtherCurrentBorrowings | 1.93B | 600.00K | 1.93B | 1.25B |
| LineOfCredit | 0.00 | 318.50M | ||
| CommercialPaper | 0.00 | 1.17B | ||
| CurrentNotesPayable | 0.00 | |||
| CurrentProvisions | 888.80M | 1.36B | ||
| PayablesAndAccruedExpenses | 4.07B | 4.35B | 4.35B | 4.18B |
| CurrentAccruedExpenses | 2.19B | 2.30B | 2.19B | 2.11B |
| InterestPayable | 52.90M | 49.90M | 66.80M | 80.20M |
| Payables | 1.88B | 2.05B | 2.17B | 2.07B |
| OtherPayable | 460.40M | 498.40M | 556.80M | 608.60M |
| DuetoRelatedPartiesCurrent | 23.80M | 22.50M | 0.00 | |
| TotalTaxPayable | 124.00M | 192.70M | 226.80M | 279.60M |
| IncomeTaxPayable | 124.00M | 192.70M | 226.80M | 279.60M |
| AccountsPayable | 1.29B | 1.36B | 1.38B | 1.16B |
| TotalAssets | 37.19B | 41.50B | 47.69B | 50.02B |
| TotalNonCurrentAssets | 27.40B | 31.98B | 34.71B | 39.39B |
| OtherNonCurrentAssets | 785.60M | 754.00M | 821.10M | 753.30M |
| NonCurrentDeferredAssets | 1.06B | 753.00M | 692.90M | 1.23B |
| NonCurrentDeferredTaxesAssets | 1.06B | 753.00M | 692.90M | 925.90M |
| InvestmentsAndAdvances | 815.00M | 1.35B | 1.14B | 1.09B |
| InvestmentinFinancialAssets | 815.00M | 1.35B | 1.14B | 1.09B |
| AvailableForSaleSecurities | 815.00M | 1.35B | 1.14B | 1.09B |
| LongTermEquityInvestment | 94.00M | 81.40M | ||
| GoodwillAndOtherIntangibleAssets | 21.86B | 26.20B | 29.05B | 33.03B |
| OtherIntangibleAssets | 15.10B | 17.07B | 19.18B | 22.61B |
| Goodwill | 6.75B | 9.13B | 9.87B | 10.43B |
| NetPPE | 2.89B | 2.92B | 3.01B | 3.28B |
| AccumulatedDepreciation | -2.52B | -2.20B | -2.01B | -2.06B |
| GrossPPE | 5.41B | 5.12B | 5.02B | 5.34B |
| ConstructionInProgress | 448.50M | 397.10M | 431.20M | 474.00M |
| OtherProperties | 271.30M | 253.10M | 245.60M | 259.30M |
| MachineryFurnitureEquipment | 3.04B | 2.89B | 2.77B | 2.94B |
| BuildingsAndImprovements | 1.53B | 1.46B | 1.44B | 1.54B |
| LandAndImprovements | 114.90M | 113.20M | 120.20M | 133.40M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 9.79B | 9.52B | 12.98B | 10.64B |
| OtherCurrentAssets | 136.20M | 387.20M | 271.00M | 328.40M |
| AssetsHeldForSaleCurrent | 0.00 | 2.79B | 230.30M | 0.00 |
| CurrentDeferredAssets | 568.30M | 526.60M | 1.07B | 747.20M |
| CurrentDeferredTaxesAssets | 568.30M | 526.60M | 747.30M | 747.20M |
| PrepaidAssets | 225.40M | 140.90M | 155.90M | 194.60M |
| Inventory | 4.00B | 3.85B | 3.47B | 3.52B |
| FinishedGoods | 2.09B | 1.98B | 2.14B | 2.19B |
| WorkInProcess | 491.70M | 527.30M | 602.10M | 755.40M |
| RawMaterials | 1.42B | 1.35B | 731.70M | 571.50M |
| Receivables | 3.35B | 3.52B | 4.04B | 4.14B |
| OtherReceivables | 453.70M | 546.00M | 876.60M | 570.70M |
| TaxesReceivable | 315.80M | 300.70M | 340.20M | 328.40M |
| AccountsReceivable | 2.58B | 2.68B | 2.82B | 3.24B |
| AllowanceForDoubtfulAccountsReceivable | -136.00M | -107.60M | -118.80M | -114.70M |
| GrossAccountsReceivable | 2.71B | 2.78B | 2.94B | 3.36B |
| CashCashEquivalentsAndShortTermInvestments | 1.51B | 1.09B | 1.18B | 1.47B |
| OtherShortTermInvestments | 190.60M | 355.10M | 192.50M | 212.60M |
| CashAndCashEquivalents | 1.32B | 734.80M | 991.90M | 1.26B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 1.85B | 1.94B | 2.33B | 2.51B |
| RepurchaseOfCapitalStock | -500.50M | -250.00M | -250.00M | 0.00 |
| RepaymentOfDebt | -100.00K | -3.71B | -1.25B | -3.66B |
| IssuanceOfDebt | 0.00 | 0.00 | 300.00K | 1.88B |
| IssuanceOfCapitalStock | 2.60M | 2.50M | 3.10M | 3.30M |
| CapitalExpenditure | -465.10M | -359.10M | -574.90M | -489.40M |
| InterestPaidSupplementalData | 492.60M | 561.10M | 611.60M | 642.50M |
| IncomeTaxPaidSupplementalData | 514.00M | 570.90M | 735.20M | 641.70M |
| EndCashPosition | 1.35B | 736.10M | 993.60M | 1.26B |
| BeginningCashPosition | 736.10M | 993.60M | 1.26B | 706.20M |
| EffectOfExchangeRateChanges | 17.60M | -30.70M | -2.50M | -38.90M |
| ChangesInCash | 594.30M | -226.80M | -266.40M | 595.20M |
| FinancingCashFlow | -1.29B | -4.33B | -2.30B | -3.88B |
| CashFlowFromContinuingFinancingActivities | -1.29B | -4.33B | -2.30B | -3.88B |
| NetOtherFinancingCharges | -234.90M | 205.60M | -229.80M | -19.50M |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | ||
| CashDividendsPaid | -561.20M | -574.80M | -575.60M | -581.60M |
| CommonStockDividendPaid | -561.20M | -574.80M | -575.60M | -581.60M |
| NetCommonStockIssuance | -497.90M | -247.50M | -246.90M | 3.30M |
| CommonStockPayments | -500.50M | -250.00M | -250.00M | 0.00 |
| CommonStockIssuance | 2.60M | 2.50M | 3.10M | 3.30M |
| NetIssuancePaymentsOfDebt | 100.00K | -3.71B | -1.25B | -3.28B |
| NetShortTermDebtIssuance | 200.00K | 0.00 | 300.00K | -1.49B |
| NetLongTermDebtIssuance | -100.00K | -3.71B | -1.25B | -1.79B |
| LongTermDebtPayments | -100.00K | -3.71B | -1.25B | -3.66B |
| LongTermDebtIssuance | 0.00 | 0.00 | 300.00K | 1.88B |
| InvestingCashFlow | -427.70M | 1.80B | -864.50M | 1.47B |
| CashFlowFromContinuingInvestingActivities | -427.70M | 1.80B | -864.50M | 1.47B |
| NetOtherInvestingChanges | 2.50M | 2.51B | 364.10M | 1.95B |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 0.00 | -300.00K |
| SaleOfInvestment | 23.90M | 26.00M | 26.30M | 29.90M |
| PurchaseOfInvestment | -23.90M | -26.00M | -26.30M | -30.20M |
| NetBusinessPurchaseAndSale | 0.00 | -350.00M | -667.70M | 0.00 |
| PurchaseOfBusiness | 0.00 | -350.00M | -667.70M | 0.00 |
| NetIntangiblesPurchaseAndSale | -86.30M | -33.10M | -197.90M | -83.40M |
| PurchaseOfIntangibles | -86.30M | -33.10M | -197.90M | -83.40M |
| NetPPEPurchaseAndSale | 34.90M | 2.70M | 14.00M | 13.80M |
| SaleOfPPE | 34.90M | 2.70M | 14.00M | 13.80M |
| CapitalExpenditureReported | -378.80M | -326.00M | -377.00M | -406.00M |
| OperatingCashFlow | 2.32B | 2.30B | 2.90B | 3.00B |
| CashFlowFromContinuingOperatingActivities | 2.32B | 2.30B | 2.90B | 3.00B |
| ChangeInWorkingCapital | -686.40M | -318.60M | -711.30M | -922.60M |
| ChangeInOtherWorkingCapital | -746.60M | 68.70M | -491.30M | -593.00M |
| ChangeInPayablesAndAccruedExpense | -168.00M | 36.00M | 314.70M | 170.20M |
| ChangeInPayable | -168.00M | 36.00M | 314.70M | 170.20M |
| ChangeInAccountPayable | -168.00M | 36.00M | 314.70M | 170.20M |
| ChangeInInventory | -106.40M | -723.40M | -613.30M | -259.50M |
| ChangeInReceivables | 334.60M | 300.10M | 78.60M | -240.30M |
| ChangesInAccountReceivables | 334.60M | 300.10M | 78.60M | -240.30M |
| OtherNonCashItems | 929.10M | 572.20M | 682.20M | 432.60M |
| StockBasedCompensation | 177.70M | 146.10M | 180.70M | 116.40M |
| AssetImpairmentCharge | 2.94B | 321.00M | 580.10M | |
| DeferredTax | -476.50M | -767.60M | -387.10M | -25.90M |
| DeferredIncomeTax | -476.50M | -767.60M | -387.10M | -25.90M |
| DepreciationAmortizationDepletion | 2.80B | 2.89B | 2.74B | 3.03B |
| DepreciationAndAmortization | 2.80B | 2.89B | 2.74B | 3.03B |
| OperatingGainsLosses | 151.80M | 411.80M | 340.30M | -1.71B |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | 61.90M | |
| GainLossOnSaleOfPPE | 50.80M | 12.30M | 100.40M | 46.40M |
| GainLossOnSaleOfBusiness | 101.00M | 399.50M | 239.90M | -1.75B |
| NetIncomeFromContinuingOperations | -3.51B | -634.20M | 54.70M | 2.08B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VTRS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|